Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility-Reference-Cited by-同舟云学术

Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility

Published:2017-07-11 Issue:9 Volume:20 Page:962-973
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Montgomery Stephen M.¹^ORCID,Kusel Jeanette¹,Nicholas Richard²,Adlard Nicholas³

Affiliation:

1. Costello Medical Consulting Ltd, Cambridge, UK;

2. Imperial College Healthcare NHS Trust, Charing Cross Hospital, London, UK;

3. Novartis Pharmaceuticals UK Ltd, Camberley, Surrey, UK

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2017.1345748

Reference37 articles.

1. Multiple sclerosis

2. Defining the clinical course of multiple sclerosis: Results of an international survey

3. Natural, innate improvements in multiple sclerosis disability

4. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

5. Overview of magnetic resonance imaging for management of relapsing−remitting multiple sclerosis in everyday practice

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. To wait, or too late? Modeling the effects of delayed ofatumumab treatment in relapsing-remitting multiple sclerosis;Journal of Medical Economics;2023-01-18

2. Ofatumumab subcutaneous injection for the treatment of relapsing forms of multiple sclerosis;Expert Review of Clinical Immunology;2022-02-01

3. Modeling the Cost-Utility of Treatment Sequences for Multiple Sclerosis;Value in Health;2021-11

4. How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review;Neurology and Therapy;2021-07-19

5. Incorporating patients’ preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review;Expert Review of Pharmacoeconomics & Outcomes Research;2021-02-02